Disc Medicine (NASDAQ:IRON) Price Target Raised to $100.00 at Wedbush

Disc Medicine (NASDAQ:IRON) had its price target lifted by equities researchers at Wedbush from $88.00 to $100.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price objective indicates a potential upside of 27.11% from the company’s previous close.

IRON has been the subject of a number of other research reports. Wall Street Zen lowered Disc Medicine from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Disc Medicine in a report on Tuesday. HC Wainwright boosted their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a research note on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $107.70.

Disc Medicine Stock Performance

NASDAQ IRON opened at $78.67 on Wednesday. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The company has a market capitalization of $3.02 billion, a P/E ratio of -11.96 and a beta of 0.98. The company has a fifty day moving average of $77.30 and a 200-day moving average of $70.09.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, equities research analysts predict that Disc Medicine will post -6.61 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In other news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the sale, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,758,677.56. This represents a 25.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $70.22, for a total value of $526,650.00. Following the completion of the sale, the insider directly owned 52,173 shares of the company’s stock, valued at $3,663,588.06. The trade was a 12.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 153,612 shares of company stock worth $11,431,811 in the last quarter. 3.76% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently modified their holdings of IRON. State of Wyoming purchased a new stake in Disc Medicine in the second quarter worth $25,000. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine in the 4th quarter worth about $33,000. Allworth Financial LP purchased a new position in Disc Medicine in the 2nd quarter worth about $46,000. Nykredit A S purchased a new stake in Disc Medicine in the 2nd quarter valued at about $103,000. Finally, Persistent Asset Partners Ltd bought a new position in Disc Medicine in the 4th quarter worth about $141,000. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.